Englander Institute for Precision Medicine

The DNA Damage Response and Inflammation in Cancer.

TitleThe DNA Damage Response and Inflammation in Cancer.
Publication TypeJournal Article
Year of Publication2023
AuthorsKlapp V, Álvarez-Abril B, Leuzzi G, Kroemer G, Ciccia A, Galluzzi L
JournalCancer Discov
Volume13
Issue7
Pagination1521-1545
Date Published2023 Jul 07
ISSN2159-8290
Abstract

UNLABELLED: Genomic stability in normal cells is crucial to avoid oncogenesis. Accordingly, multiple components of the DNA damage response (DDR) operate as bona fide tumor suppressor proteins by preserving genomic stability, eliciting the demise of cells with unrepairable DNA lesions, and engaging cell-extrinsic oncosuppression via immunosurveillance. That said, DDR sig-naling can also favor tumor progression and resistance to therapy. Indeed, DDR signaling in cancer cells has been consistently linked to the inhibition of tumor-targeting immune responses. Here, we discuss the complex interactions between the DDR and inflammation in the context of oncogenesis, tumor progression, and response to therapy.

SIGNIFICANCE: Accumulating preclinical and clinical evidence indicates that DDR is intimately connected to the emission of immunomodulatory signals by normal and malignant cells, as part of a cell-extrinsic program to preserve organismal homeostasis. DDR-driven inflammation, however, can have diametrically opposed effects on tumor-targeting immunity. Understanding the links between the DDR and inflammation in normal and malignant cells may unlock novel immunotherapeutic paradigms to treat cancer.

DOI10.1158/2159-8290.CD-22-1220
Alternate JournalCancer Discov
PubMed ID37026695
Grant List#BC180476P1 / / U.S. Department of Defense (DOD) /
#BC210945 / / U.S. Department of Defense (DOD) /
#I16-0064 / / Starr Consortium /

Weill Cornell Medicine Englander Institute for Precision Medicine 413 E 69th Street
Belfer Research Building
New York, NY 10021